Prevention of atherothrombotic events after myocardial infarction in adults. (NICE TA420)
Ticagrelor, in combination with aspirin, is recommended within its marketing authorisation as an option for preventing atherothrombotic events in adults who had a myocardial infarction and who are at high risk of a further event. Treatment should be stopped when clinically indicated or at a maximum of 3 years.
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist